Physician profile
Stephen A Norris
NPI 1043271992
$489.11
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $65.54 · 2021: $63.50 · 2022: $88.92 · 2023: $58.37 · 2024: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $163.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $99.65 | 2019-2023 | Rybelsus, Ozempic |
| Smith+Nephew, INC. | $97.17 | 2019-2023 | Collagenase Santyl, Regranex |
| Stryker Corporation | $56.64 | 2024 | Ortholoc 2 Lapifuse, 7 X 23mm Citrelock Implant |
| Merck Sharp & Dohme LLC | $30.71 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Dexcom, INC. | $30.08 | 2024 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $25.56 | 2021 | |
| Kerecis Limited | $17.95 | 2020 | |
| Idorsia Pharmaceuticals US INC | $16.55 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $16.03 | 2020 | |
| Kci USA, INC. | $16.00 | 2020 | |
| Sanofi Pasteur INC. | $14.64 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.42 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.40 | 2022 | |
| Lilly USA, LLC | $13.97 | 2023 | Mounjaro, Trulicity |
| Osiris Therapeutics INC. | $13.67 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Norris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.